Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy.
Antibodies, Monoclonal, Humanized
/ pharmacology
Benzylamines
Chemokines, CC
/ metabolism
Chemokines, CXC
/ metabolism
Cyclams
Heterocyclic Compounds
/ pharmacology
Humans
Immunotherapy
/ methods
Molecular Targeted Therapy
/ methods
Neoplasms
/ immunology
Receptors, CCR
/ antagonists & inhibitors
Receptors, CXCR
/ antagonists & inhibitors
atypical chemokine receptor
cancer related inflammation
chemokine
chemokine receptor
immunotherapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
11
2018
accepted:
14
02
2019
entrez:
22
3
2019
pubmed:
22
3
2019
medline:
20
6
2020
Statut:
epublish
Résumé
Immunotherapy is a clinically validated treatment for many cancers to boost the immune system against tumor growth and dissemination. Several strategies are used to harness immune cells: monoclonal antibodies against tumor antigens, immune checkpoint inhibitors, vaccination, adoptive cell therapies (e.g., CAR-T cells) and cytokine administration. In the last decades, it is emerging that the chemokine system represents a potential target for immunotherapy. Chemokines, a large family of cytokines with chemotactic activity, and their cognate receptors are expressed by both cancer and stromal cells. Their altered expression in malignancies dictates leukocyte recruitment and activation, angiogenesis, cancer cell proliferation, and metastasis in all the stages of the disease. Here, we review first attempts to inhibit the chemokine system in cancer as a monotherapy or in combination with canonical or immuno-mediated therapies. We also provide recent findings about the role in cancer of atypical chemokine receptors that could become future targets for immunotherapy.
Identifiants
pubmed: 30894861
doi: 10.3389/fimmu.2019.00379
pmc: PMC6414456
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Benzylamines
0
Chemokines, CC
0
Chemokines, CXC
0
Cyclams
0
Heterocyclic Compounds
0
Receptors, CCR
0
Receptors, CXCR
0
plerixafor
S915P5499N
mogamulizumab
YI437801BE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
379Références
Am J Pathol. 2000 Mar;156(3):831-7
pubmed: 10702399
Am J Pathol. 2001 Mar;158(3):867-77
pubmed: 11238036
Blood. 2003 Jul 1;102(1):311-9
pubmed: 12649140
Int J Cancer. 2003 Jun 10;105(2):186-9
pubmed: 12673677
J Exp Med. 2003 Nov 3;198(9):1337-47
pubmed: 14581607
J Immunol. 2004 Apr 15;172(8):4972-6
pubmed: 15067078
FASEB J. 2004 Aug;18(11):1240-2
pubmed: 15180966
BMC Cancer. 2004 Jun 23;4:28
pubmed: 15214968
Nat Rev Cancer. 2004 Jul;4(7):540-50
pubmed: 15229479
Cancer Res. 2004 Dec 1;64(23):8604-12
pubmed: 15574767
Cancer Res. 2005 Jan 15;65(2):465-72
pubmed: 15695388
J Immunother. 2005 Jul-Aug;28(4):343-51
pubmed: 16000952
Cytokine Growth Factor Rev. 2005 Dec;16(6):593-609
pubmed: 16046180
FASEB J. 2006 Jan;20(1):59-64
pubmed: 16394268
Oncogene. 2006 Nov 16;25(54):7201-11
pubmed: 16785997
Nat Rev Immunol. 2006 Dec;6(12):907-18
pubmed: 17124512
J Cell Biochem. 2007 Jun 1;101(3):676-85
pubmed: 17216598
Cancer Res. 2007 Jan 15;67(2):651-8
pubmed: 17234775
Immunol Res. 2006;36(1-3):61-72
pubmed: 17337767
J Clin Invest. 2007 Jul;117(7):1884-92
pubmed: 17607362
Blood. 2007 Nov 15;110(10):3744-52
pubmed: 17715391
Clin Exp Metastasis. 2008;25(4):345-56
pubmed: 17891505
J Biol Chem. 2008 Feb 15;283(7):4283-94
pubmed: 18057003
Cancer Biol Ther. 2008 Jul;7(7):1037-43
pubmed: 18437055
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Cancer Res. 2008 Oct 15;68(20):8437-45
pubmed: 18922917
Blood. 2009 Jun 11;113(24):6206-14
pubmed: 19050309
Nat Rev Drug Discov. 2009 Jan;8(1):23-33
pubmed: 19079127
Curr Pharm Biotechnol. 2009 Feb;10(2):166-84
pubmed: 19199949
Cancer Res. 2009 Mar 1;69(5):2000-9
pubmed: 19244125
Clin Cancer Res. 2009 May 1;15(9):2962-70
pubmed: 19383822
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Gut. 2010 Feb;59(2):197-206
pubmed: 19846409
Cytokine Growth Factor Rev. 2010 Feb;21(1):27-39
pubmed: 20004131
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):628-32
pubmed: 20018651
Adv Cancer Res. 2010;106:91-111
pubmed: 20399957
Clin Cancer Res. 2010 Jun 1;16(11):2927-31
pubmed: 20484021
Blood. 2010 Nov 18;116(20):4130-40
pubmed: 20562329
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13063-8
pubmed: 20616008
J Leukoc Biol. 2011 Jan;89(1):31-9
pubmed: 20628066
Cancer Metastasis Rev. 2010 Dec;29(4):709-22
pubmed: 20839032
Cancer Res. 2011 Aug 15;71(16):5522-5534
pubmed: 21742774
Nat Rev Immunol. 2011 Aug 25;11(9):597-606
pubmed: 21866172
J Pathol. 2012 Jan;226(2):148-57
pubmed: 21989643
Semin Cancer Biol. 2012 Feb;22(1):33-40
pubmed: 22210179
Breast Cancer Res. 2012 Jan 18;14(1):R14
pubmed: 22251626
Blood. 2012 Apr 26;119(17):3917-24
pubmed: 22308295
Pathol Int. 2012 May;62(5):309-17
pubmed: 22524658
Blood. 2012 Aug 16;120(7):1449-57
pubmed: 22618707
Oncoimmunology. 2012 Jan 1;1(1):106-108
pubmed: 22720226
Oncoimmunology. 2012 Jul 1;1(4):531-532
pubmed: 22754775
Invest New Drugs. 2013 Jun;31(3):760-8
pubmed: 22907596
Cancer Res. 2013 Feb 1;73(3):1128-41
pubmed: 23221383
Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50
pubmed: 23385782
Mol Cancer Ther. 2013 May;12(5):799-808
pubmed: 23468530
PLoS One. 2013;8(3):e58426
pubmed: 23484027
Clin Cancer Res. 2013 Jul 1;19(13):3495-507
pubmed: 23637121
Oncogene. 2014 May 29;33(22):2898-908
pubmed: 23873025
J Pathol. 2014 Jan;232(1):43-56
pubmed: 24014111
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Int J Biol Markers. 2014 Mar 24;29(1):e40-8
pubmed: 24338720
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Clin Cancer Res. 2014 Jul 1;20(13):3581-8
pubmed: 24727324
Cancer Immunol Res. 2014 Jul;2(7):679-89
pubmed: 24844911
Cytokine Growth Factor Rev. 2014 Jun;25(3):307-16
pubmed: 24853339
Biomed Res Int. 2014;2014:768758
pubmed: 24971349
Cell Death Dis. 2014 Jul 03;5:e1310
pubmed: 24991762
Immunol Cell Biol. 2014 Nov;92(10):815-24
pubmed: 25027038
Nature. 2014 Nov 6;515(7525):134-7
pubmed: 25156255
J Pathol. 2015 Mar;235(4):546-58
pubmed: 25255875
Expert Opin Ther Targets. 2014 Nov;18(11):1265-75
pubmed: 25256399
EMBO J. 2014 Nov 3;33(21):2564-80
pubmed: 25271254
Nature. 2014 Nov 6;515(7525):130-3
pubmed: 25337873
Immunobiology. 2015 Feb;220(2):249-53
pubmed: 25454487
Cancer Immunol Res. 2014 Dec;2(12):1125-31
pubmed: 25480554
Mol Cancer Ther. 2015 Feb;14(2):480-90
pubmed: 25504752
Cancer Lett. 2015 Apr 28;360(1):60-7
pubmed: 25676691
Cardiovasc Res. 2015 Aug 1;107(3):364-72
pubmed: 25969393
Blood. 2015 Jul 9;126(2):222-32
pubmed: 26031918
Front Immunol. 2015 Jun 05;6:279
pubmed: 26097477
Clin Cancer Res. 2015 Oct 1;21(19):4278-85
pubmed: 26199389
Oncogene. 2016 Apr 21;35(16):2123-32
pubmed: 26212008
PLoS One. 2015 Sep 28;10(9):e0139237
pubmed: 26414070
Oncotarget. 2015 Oct 27;6(33):34758-73
pubmed: 26416449
Gut. 2017 Jan;66(1):157-167
pubmed: 26452628
Endocr Relat Cancer. 2016 Feb;23(2):113-24
pubmed: 26559672
Oncol Rep. 2016 Mar;35(3):1557-65
pubmed: 26707275
Int J Clin Exp Pathol. 2015 Oct 01;8(10):12533-40
pubmed: 26722441
Int J Oncol. 2016 Apr;48(4):1341-52
pubmed: 26847910
J Leukoc Biol. 2016 Jun;99(6):927-33
pubmed: 26908826
Cytokine Growth Factor Rev. 2016 Aug;30:81-6
pubmed: 27021826
Methods Mol Biol. 2016;1393:87-96
pubmed: 27033218
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Cancer Cell. 2016 Apr 11;29(4):587-601
pubmed: 27070705
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Clin Cancer Res. 2017 Jan 1;23(1):137-148
pubmed: 27354473
Ann Transl Med. 2016 Jul;4(14):261
pubmed: 27563648
Cancer Immunol Res. 2016 Nov;4(11):968-982
pubmed: 27737879
Int J Mol Sci. 2016 Nov 08;17(11):
pubmed: 27834814
Stem Cell Investig. 2016 Oct 31;3:70
pubmed: 27868052
J Hematol Oncol. 2017 Jan 5;10(1):5
pubmed: 28057017
Cancer Immunol Res. 2017 Mar;5(3):182-190
pubmed: 28108630
J Clin Invest. 2017 Mar 1;127(3):801-813
pubmed: 28134623
Nat Rev Nephrol. 2017 Apr;13(4):192
pubmed: 28190878
J Exp Med. 2017 Jun 5;214(6):1691-1710
pubmed: 28450382
BMC Biol. 2017 May 19;15(1):45
pubmed: 28526034
Clin Cancer Res. 2017 Sep 15;23(18):5358-5365
pubmed: 28539464
Am J Hematol. 2017 Sep;92(9):892-901
pubmed: 28543380
Oncol Rep. 2017 Sep;38(3):1393-1401
pubmed: 28713975
Am J Pathol. 2017 Sep;187(9):2080-2094
pubmed: 28734730
Genes Cancer. 2017 May;8(5-6):577-588
pubmed: 28740576
EBioMedicine. 2017 Aug;22:58-67
pubmed: 28754304
Cancer Res. 2017 Oct 1;77(19):5215-5221
pubmed: 28928130
Front Immunol. 2017 Oct 26;8:1349
pubmed: 29123517
Cell Rep. 2017 Nov 21;21(8):2212-2222
pubmed: 29166611
Gut. 2018 Jun;67(6):1112-1123
pubmed: 29196437
Blood Adv. 2017 Jun 21;1(15):1088-1100
pubmed: 29296751
Cancer Discov. 2018 Feb;8(2):OF1
pubmed: 29298770
Med Sci Monit. 2018 Jan 21;24:405-411
pubmed: 29353287
Haematologica. 2018 May;103(5):e211-e214
pubmed: 29371324
Cancer Immunol Res. 2018 Jan 30;:null
pubmed: 29382671
Biol Blood Marrow Transplant. 2018 Jun;24(6):1187-1195
pubmed: 29410180
Nat Commun. 2018 Feb 14;9(1):676
pubmed: 29445158
Cancer Immunol Res. 2018 May;6(5):539-551
pubmed: 29511032
Mol Ther. 2018 May 2;26(5):1354-1365
pubmed: 29606504
Lancet Oncol. 2018 Jun;19(6):812-824
pubmed: 29706375
J Immunol. 2018 Oct 15;201(8):2510-2519
pubmed: 30158126
Int J Cancer. 2018 Dec 1;143(11):3008-3018
pubmed: 30183073
Mol Cancer Res. 2019 Feb;17(2):604-617
pubmed: 30446625
Front Immunol. 2018 Nov 27;9:2750
pubmed: 30542347